Alliqua BioMedical’s $29 million asset purchase agreement with Celularity, Inc.

Haynes and Boone, LLP represented Alliqua BioMedical, Inc. in a $29 million asset purchase agreement with Celularity, Inc.

The agreement, which is subject to stockholder approval, calls for Celularity to acquire all of the property, assets and rights relating to Alliqua’s advanced biologic wound care business — including Biovance® amniotic membrane allograft and Interfyl® Human Connective Tissue Matrix — and the company’s UltraMist® Therapy System and other therapeutic ultrasound platform products for an aggregate cash consideration of $29 million.

Alliqua’s announcement said the agreement includes all intellectual property and all license, marketing, development and supply agreements related to the businesses.

Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company, led by David Ian Johnson, Brian M. Posner, Bradford C. Barton and Pellegrino Pionati, is based in Yardley (PA).

Haynes and Boone, LLP advised with a team including Rick Werner (Picture), Greg Kramer and Patrick Horan.

Involved fees earner: Rick Werner – Haynes and Boone; Greg Kramer – Haynes and Boone; Patrick Horan – Haynes and Boone;

Law Firms: Haynes and Boone;

Clients: Alliqua BioMedical, Inc.;


Author: Ambrogio Visconti